MYTX-011 is under clinical development by Mythic Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MYTX-011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MYTX-011 overview

MYTX-011 are under development for the treatment of non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancers, squamous non-small cell lung cancer, bladder, kidney and skin cancer. MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE). They are being developed based on FateControl technology. It is administered through intravenous route. It acts by targeting hepatocyte growth factor receptor (c Met).

Mythic Therapeutics overview

Mythic Therapeutics is a biotechnology company that focused on a new generation of groundbreaking cancer therapeutics. Mythic Therapeutics is headquartered in Waltham, Massachusetts, the US.

For a complete picture of MYTX-011’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.